E5555 + E5555 + E5555 + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Coronary Syndrome
Conditions
Acute Coronary Syndrome
Trial Timeline
Nov 1, 2007 → —
NCT ID
NCT00619164About E5555 + E5555 + E5555 + Placebo
E5555 + E5555 + E5555 + Placebo is a phase 2 stage product being developed by Eisai for Acute Coronary Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00619164. Target conditions include Acute Coronary Syndrome.
What happened to similar drugs?
20 of 20 similar drugs in Acute Coronary Syndrome were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00619164 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Coronary Syndrome